乐观
$12.30
情景价格
$17.770
-0.158 (-0.89%)收盘时
Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company's segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Its Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
Sotera Health Co (SHC) is currently trading at $17.89, which is below the average analyst price target of $20. However, the stock has a relatively low RSI of 41.764, indicating it may not be oversold yet. The forward P/E ratio of 17.762 suggests that the stock is reasonably valued compared to its earnings potential. The recent insider activity is neutral, and while hedge funds have increased their buying by 140.83%, the company faces risks such as organic growth weakness, with a mere 4.9% average growth over the past two years, and limited distribution channels that could hinder expansion. Therefore, while there are positive indicators, the risks suggest a hold position for now.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Sotera Health to Release Q3 Financial Results on November 3, 2026

Sotera Health Q2 Earnings Analysis: Buy, Sell, or Hold?

Sotera Health (SHC) Q2 2026 Earnings Call Transcript

Sotera Health Q2 Results Exceed Expectations

Sotera Health Q2 2026 Earnings Highlights
Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company's segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Its Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).
Sotera Health Co (SHC) is currently trading at $17.89, which is below the average analyst price target of $20. However, the stock has a relatively low RSI of 41.764, indicating it may not be oversold yet. The forward P/E ratio of 17.762 suggests that the stock is reasonably valued compared to its earnings potential. The recent insider activity is neutral, and while hedge funds have increased their buying by 140.83%, the company faces risks such as organic growth weakness, with a mere 4.9% average growth over the past two years, and limited distribution channels that could hinder expansion. Therefore, while there are positive indicators, the risks suggest a hold position for now.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。